{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-016725","form_type":"8-K","ticker":"XXII","cik":"0001347858","company_name":"22nd Century Group, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.290550+00:00","generated_at":"2026-06-22T03:07:53.688041+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"22nd Century Q3 revenue up 148% to $19.4M; net loss $13.1M, VLN expansion to 12-18 states","bullets":["Net revenue $19.4M (+148% YoY); tobacco $11.5M (+47.7%), hemp/cannabis $7.8M (new).","Operating loss widened to $15.3M from $7.6M; net loss $13.1M ($0.06/share).","VLN cigarette launch expands to CO, AZ, NM, UT; targeting 12-18 states within 12 months.","Full quarter of GVB Biopharma revenue included; GVB passed NSF audit, pursuing pharma-grade certifications.","Cash and investments $43.7M; manufacturing capacity +25%; largest VLN tobacco crop planted."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-016725","json":"https://secwatch.observer/filing/0001558370-22-016725.json","markdown":"https://secwatch.observer/filing/0001558370-22-016725.md","text":"https://secwatch.observer/filing/0001558370-22-016725.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347858/000155837022016725/0001558370-22-016725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347858/000155837022016725/xxii-20221108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:07:53.688041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d3e5886cb15f832c6b5353b23d221ac0b8959c4","claim":"22nd Century Group, Inc. reported the third quarter ended September 30, 2022 results: revenue $19.4 Million.","evidence_excerpt":"and Illinois, Launching in Four Corners States to Capture Market Share and Volume ● GVB Biopharma Acquisition Growing Revenue on Increased Volumes ● Third Quarter Net Sales $19.4 Million, Up 148% from the Third Quarter 2021 ● Strong Balance Sheet to Support Strategic Initiatives Including Accelerated VLN ® Expansion ​ BUFFALO, N.Y., November 8, 2022 (Globe","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347858/000155837022016725/0001558370-22-016725-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$19.4 Million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}